Document Detail

Management of severe refractory adult autoimmune enteropathy with infliximab and tacrolimus.
MedLine Citation:
PMID:  15785040     Owner:  NLM     Status:  MEDLINE    
INTRODUCTION: Autoimmune enteropathy (AIE) is a rare cause of intractable diarrhea in infancy. A variant with onset in adulthood has recently been described. The immune mechanisms underlying AIE are unclear and the experience in the management of adult AIE is very limited. CASE REPORT: A 19-year-old male patient with massive refractory diarrhea and significant weight loss was diagnosed with AIE. He did not improve with corticosteroid and azathioprine treatment and was then treated successfully with infliximab. The response to treatment was rapid and complete. Because of a severe life-threatening hypersensitivity reaction during the 4th infliximab dose, infliximab had to be discontinued and therapy with tacrolimus was initiated. A complete clinical remission has since been maintained. CONCLUSION: Both infliximab and tacrolimus may provide a therapeutic alternative in patients with adult refractory AIE.
Thomas von Hahn; Dieter Stopik; Martin Koch; Bertram Wiedenmann; Axel Dignass
Publication Detail:
Type:  Case Reports; Journal Article     Date:  2005-03-22
Journal Detail:
Title:  Digestion     Volume:  71     ISSN:  0012-2823     ISO Abbreviation:  Digestion     Publication Date:  2005  
Date Detail:
Created Date:  2005-07-01     Completed Date:  2005-09-13     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0150472     Medline TA:  Digestion     Country:  Switzerland    
Other Details:
Languages:  eng     Pagination:  141-4     Citation Subset:  IM    
Department of Internal Medicine, Divisions of Gastroenterology and Hepatology, Charité Medical School-Campus Virchow, Augustenburger Platz 1, DE-13353 Berlin, Germany.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Administration, Oral
Antibodies, Monoclonal / administration & dosage,  therapeutic use*
Autoimmune Diseases / drug therapy*,  pathology
Drug Therapy, Combination
Endoscopy, Gastrointestinal
Follow-Up Studies
Gastrointestinal Agents / administration & dosage,  therapeutic use*
Immunosuppressive Agents / administration & dosage,  therapeutic use*
Infusions, Intravenous
Intestinal Diseases / drug therapy*,  pathology
Intestinal Mucosa / pathology
Severity of Illness Index
Tacrolimus / administration & dosage,  therapeutic use*
Treatment Outcome
Reg. No./Substance:
0/Antibodies, Monoclonal; 0/Gastrointestinal Agents; 0/Immunosuppressive Agents; 0/infliximab; 109581-93-3/Tacrolimus

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Effects of the tyrosine kinase inhibitor imatinib on neuroendocrine tumor cell growth.
Next Document:  A new era in the management of psoriasis? Promises and facts.